Nouscom

Nouscom

Backed by international life sciences investors, Nouscom was founded in 2015 and is headquartered in Basel, Switzerland. A clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies, Nouscom uses a proprietary viral vector platform which has the capacity to encode for large payloads of neoantigens to safely and potently harness the power of the immune system.
More Details

Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently harness the power of the immune system. The Company announced in November 2023 that it had raised financing in an oversubscribed Series ‘C’ round to advance the clinical development of its wholly owned programs: NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors in combination with pembrolizumab in randomized Phase 2 trials. In January 2023, Nouscom announced a clinical trial collaboration and pembrolizumab supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA). NOUS-209, an off-the-shelf monotherapy in Lynch Syndrome carriers with the potential to ‘intercept cancer’ before it occurs. A Phase 1b is being conducted under a clinical trial collaboration and supply agreement signed in 2022 with the National Cancer Institute (NCI), with interim data selected presented in a late breaking oral presentation at SITC in November 2023. NOUS-PEV, a personalized cancer immunotherapy, is expected to enter randomized Phase 2 trials in indications with high unmet medical need in 2024. Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb.

6 clinical trials are actively ongoing, including a randomized Phase 2 trial of NOUS-209 for the treatment of MSI-H solid tumors in combination with pembrolizumab, a Phase 1b ‘cancer interception’ in Lynch Syndrome as well as NOUS-PEV, a personalized cancer immunotherapy that will be reporting Phase 1 data at a forthcoming scientific conference in Q2 2023. 

Nouscom has also exclusively out-licensed a third product, VAC-85135, to Janssen Oncology, which is currently under evaluation in a Phase 1 trial.

http://www.nouscom.com